Skip to main content

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NASDAQ: CRBP · IEX Real-Time Price · USD
1.04
+0.02 (1.96%)
After-hours:Oct 15, 2021 6:27 PM EDT
1.02
0.00 (0.00%)
At close: Oct 15, 4:00 PM
Market Cap127.74M
Revenue (ttm)2.67M
Net Income (ttm)-76.71M
Shares Out116.36M
EPS (ttm)-0.75
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume531,758
Open1.02
Previous Close1.02
Day's Range1.01 - 1.03
52-Week Range0.91 - 4.00
Beta1.94
AnalystsHold
Price Target2.05 (+101.0%)
Est. Earnings DateNov 8, 2021

About CRBP

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for...

IndustryBiotechnology
Founded2009
CEOYuval Cohen
Employees76
Stock ExchangeNASDAQ
Ticker SymbolCRBP
Full Company Profile

Financial Performance

In 2020, CRBP's revenue was $3.94 million, a decrease of -89.11% compared to the previous year's $36.14 million. Losses were -$111.27 million, 55.7% more than in 2019.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for CRBP stock is "Hold." The 12-month stock price forecast is 2.05, which is an increase of 100.98% from the latest price.

Price Target
$2.05
(100.98% upside)
Analyst Consensus: Hold

News

Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -25.00% and -83.57%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Recap: Corbus Pharmaceuticals Q2 Earnings

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) decreased 1.5% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 71.15% year over year to ($0.15)...

2 months ago - Benzinga

Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

Norwood, MA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company, today provided corporate updates and reported fina...

2 months ago - GlobeNewsWire

Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist

Why investors are watching these 7 penny stocks right now The post Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Informat...

Other symbols:ABUSDBGIJFUNBYNXE
3 months ago - PennyStocks

Pot Stocks in Focus: Cannabis-Based Pharmaceutical Trials

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...

3 months ago - Schaeffers Research

Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomy...

Norwood, MA, June 24, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company developing innovative medicines that target inflamm...

3 months ago - GlobeNewsWire

3 Biotech Stocks With Big Catalysts in June

Important events on the horizon could push these biotech stocks higher or press them further into the dirt.

Other symbols:GMTXNTLA
3 months ago - The Motley Fool

Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

PSY: 14 Things to Know About the First Psychedelic Stocks ETF in the U.S.

PSY (PSY) is getting extra attention on Monday as investors seek out new investments in the psychedelic medical market today. The post PSY: 14 Things to Know About the First Psychedelic Stocks ETF in th...

Other symbols:ACBCRONCWBHFTWTR
4 months ago - InvestorPlace

This Biotech Penny Stock Is Better Than Dogecoin

You might want to avoid buying it, though.

4 months ago - The Motley Fool

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases

Norwood, MA, June 01, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced licensing deals for two new monoclonal antibodies (mAbs),...

4 months ago - GlobeNewsWire

3 Biotech Penny Stocks That Are Popular on Reddit Right Now

Looking for biotech penny stocks on Reddit? Check these 3 out for your watchlist The post 3 Biotech Penny Stocks That Are Popular on Reddit Right Now appeared first on Penny Stocks to Buy, Picks, News a...

Other symbols:EYESTYME
4 months ago - PennyStocks

Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress

Norwood, MA, May 25, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medici...

4 months ago - GlobeNewsWire

CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING

Norwood, MA, May 19, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals H o ldings, Inc.  (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...

4 months ago - GlobeNewsWire

Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Don't?

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Here Are the Cannabis Stocks That Caught Fire This Week

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...

5 months ago - Schaeffers Research

Recap: Corbus Pharmaceuticals Q1 Earnings

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 67.44% year over year to ($0.14), which beat the estim...

5 months ago - Benzinga

Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates

Norwood, MA, May 13, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medici...

5 months ago - GlobeNewsWire

Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences

Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medici...

5 months ago - GlobeNewsWire

Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

4/20 Holiday Week Had These Cannabis Stocks Fired Up

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will conti...

5 months ago - Schaeffers Research

Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment o...

Norwood, MA, April 20, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medi...

5 months ago - GlobeNewsWire

The Week Where New York Legalizes Recreational Marijuana

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will conti...

Other symbols:GNLNHUGEIIPROGI
6 months ago - Schaeffers Research

Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyo...

Norwood, MA, March 30, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medi...

6 months ago - GlobeNewsWire